← Leaderboards
Trudy Hope Grossman
Cubrc, Inc.
$987,469
Attributed
$1,974,938
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $521.1K · FY2012–15$1M$750K$500K$250K$0
'12
'13
'14
'15
Funding mix
By agency
NIH$1,974,938 · 1
By mechanism
R01$1,974,938 · 1
Top collaborators
- Anne Kathleen Radcliff4 shared
Others in their field
Top investigators on “Adverse Effects”
- James Dennis Neaton · Northwestern University$203,539,316
- John M Lachin · George Washington University$139,991,329
- Elizabeth A Thom · George Washington University$126,101,581
- David M Nathan · Massachusetts Institute Of Technology$120,651,895
- Constance Ann Benson · University Of California, San Diego$114,806,215
- Wafaa M. El-Sadr · Columbia University Health Sciences$102,102,044
Research focus
Adverse EffectsAerosolizedAerosolsAftercareAmes AssayAnalogAnalytical MethodAnimalsAnti-Bacterial AgentsAntibioticsAppearanceAutopsyBacteriaBiodefenseBiological AvailabilityBiothreatBlood SpecimenBuffersCategoriesCellsClinical ChemistryCoagulation ProcessDatabasesAbcb1 Gene
Grant awards (4)
Development of TP-217 as a highly efficacious, broad-spectrum antibiotic for the$496,101
R01 · FY2015 · AI
Development of TP-217 as a highly efficacious, broad-spectrum antibiotic for the$481,592
R01 · FY2014 · AI
Development of TP-217 as a highly efficacious, broad-spectrum antibiotic for the$476,117
R01 · FY2013 · AI
Development of TP-217 as a highly efficacious, broad-spectrum antibiotic for the$521,128
R01 · FY2012 · AI